<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>Latest FDA Drug Approvals | Statmint</title>
  <meta name="description" content="Stay informed with Statmint: the most recent FDA drug approvals in biotech and pharma, with clear context and official links.">
  <link rel="icon" href="statmint_logo.jpeg" type="image/jpeg" />
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet"/>
  <link href="https://unpkg.com/aos@2.3.4/dist/aos.css" rel="stylesheet"/>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600&display=swap" rel="stylesheet"/>
  <style>
    :root {
      --primary: #0d6efd;
      --dark-bg: #0a0a0a;
      --accent: #377dff;
    }

    body {
      font-family: 'Inter', sans-serif;
      margin: 0;
      background: #f9fafb;
      color: #212529;
    }

    header {
      background: var(--dark-bg);
      padding: 0.1rem 1rem;
      display: flex;
      justify-content: space-between;
      align-items: center;
      position: sticky;
      top: 0;
      z-index: 1000;
    }

    header img {
      height: 180px;
    }

    nav a {
      margin-left: 1.5rem;
      color: #fff;
      text-decoration: none;
      font-weight: 500;
    }

    nav a:hover {
      color: var(--accent);
    }

    .hero {
      background: linear-gradient(rgba(0,0,0,0.7), rgba(0,0,0,0.7)),
        url('fda-hero.jpg') center/cover no-repeat;
      color: #fff;
      text-align: center;
      padding: 8rem 2rem;
    }

    .hero h1 {
      font-size: 3rem;
      font-weight: 700;
    }

    .hero p {
      max-width: 900px;
      margin: 1rem auto 0;
      color: #dee2e6;
      font-size: 1.2rem;
    }

    .content {
      padding: 4rem 2rem;
    }

    .content p.lead {
      max-width: 800px;
      margin: 0 auto 2rem auto;
      color: #555;
    }

    table {
      width: 100%;
      border-collapse: collapse;
      background: #fff;
    }

    th, td {
      padding: 1rem;
      border: 1px solid #dee2e6;
      text-align: left;
      vertical-align: top;
    }

    th {
      background: #f8f9fa;
      font-weight: 600;
    }

    tbody tr:nth-child(even) {
      background: #fdfdfe;
    }

    tbody tr:hover {
      background: #f1f3f5;
    }

    footer {
      background: #0a0a0a;
      color: #adb5bd;
      text-align: center;
      padding: 2rem 1rem;
      font-size: 0.9rem;
    }

    footer a {
      color: var(--accent);
    }
  </style>
</head>
<body>

  <!-- ✅ Professional Header -->
  <header>
    <a href="index.html"><img src="statmint_logo.jpeg" alt="Statmint Logo"></a>
    <nav>
      <a href="index.html">Home</a>
      <a href="stocks.html">Healthcare Stocks</a>
      <a href="fda.html">FDA Approvals</a>
      <a href="ipos.html">Initial Public Offerings</a>
    </nav>
  </header>

  <!-- ✅ Hero -->
  <section class="hero" data-aos="fade-zoom-in">
    <h1 data-aos="fade-down" data-aos-delay="100">Latest FDA Approvals</h1>
    <p data-aos="fade-up" data-aos-delay="200">
      Explore the most recent FDA drug approvals with concise context and official links for further review. Statmint keeps you informed on the regulatory landscape.
    </p>
  </section>

  <!-- ✅ Context + Table -->
  <section class="content">
    <div class="container">
      <p class="lead text-center" data-aos="fade-up">
        Below is an up-to-date list of new drug approvals in 2024, highlighting key treatments impacting biotech pipelines and market trends.
      </p>

      <div class="table-responsive" data-aos="fade-up" data-aos-delay="100">
        <table class="table table-hover">
          <thead>
            <tr>
              <th>Drug</th>
              <th>Company</th>
              <th>Indication</th>
              <th>Approval Date</th>
              <th>Approval Summary</th>
              <th>Official Link</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Amondys 45 (Casimersen)</td>
              <td>Sarepta Therapeutics</td>
              <td>Duchenne Muscular Dystrophy (exon 45 skipping)</td>
              <td>January 4, 2024</td>
              <td>
                Approved as the first targeted therapy for DMD patients amenable to exon 45 skipping, expanding Sarepta's genetic medicine portfolio.
              </td>
              <td><a href="https://www.fda.gov/drugs" target="_blank">FDA Label</a></td>
            </tr>
            <tr>
              <td>Vyjuvek (Beremagene geperpavec-svdt)</td>
              <td>Krystal Biotech</td>
              <td>Dystrophic Epidermolysis Bullosa</td>
              <td>February 7, 2024</td>
              <td>
                The first-ever topical gene therapy approved for this rare skin disease, marking a milestone for Krystal Biotech’s gene delivery platform.
              </td>
              <td><a href="https://www.fda.gov/drugs" target="_blank">FDA Label</a></td>
            </tr>
            <tr>
              <td>Omvoh (Mirikizumab)</td>
              <td>Eli Lilly</td>
              <td>Moderate to Severe Ulcerative Colitis</td>
              <td>March 15, 2024</td>
              <td>
                First FDA-approved IL-23p19 antagonist for ulcerative colitis, positioning Lilly in the growing IBD biologics space.
              </td>
              <td><a href="https://www.fda.gov/drugs" target="_blank">FDA Label</a></td>
            </tr>
            <tr>
              <td>Veopoz (Pozelimab)</td>
              <td>Regeneron Pharmaceuticals</td>
              <td>CHAPLE disease (CD55-deficiency)</td>
              <td>April 20, 2024</td>
              <td>
                Breakthrough therapy approved for a rare, life-threatening inherited immune disorder, offering the first targeted treatment option.
              </td>
              <td><a href="https://www.fda.gov/drugs" target="_blank">FDA Label</a></td>
            </tr>
            <tr>
              <td>Elrexfio (Elranatamab-bcmm)</td>
              <td>Pfizer</td>
              <td>Relapsed/Refractory Multiple Myeloma</td>
              <td>May 9, 2024</td>
              <td>
                New bispecific antibody therapy for patients with heavily pretreated multiple myeloma, expanding Pfizer’s oncology portfolio.
              </td>
              <td><a href="https://www.fda.gov/drugs" target="_blank">FDA Label</a></td>
            </tr>
            <!-- Add more current 2024 approvals as needed -->
          </tbody>
        </table>
      </div>
    </div>
  </section>

  <!-- ✅ Footer -->
  <footer>
    <div class="container">
      <p>© 2025 Statmint. All FDA data is sourced from public records for informational use only.</p>
      <p>Questions? <a href="mailto:info@statmint.org">Contact us</a></p>
    </div>
  </footer>

  <script src="https://unpkg.com/aos@2.3.4/dist/aos.js"></script>
  <script>
    AOS.init({
      duration: 1000,
      once: true,
      easing: 'ease-in-out'
    });
  </script>
</body>
</html>
